Takeda Pharmaceutical (TKPHF) EPS (Basic) (2017 - 2026)

Takeda Pharmaceutical's EPS (Basic) history runs 10 years deep, the most recent figure standing at -$14345.1 for Q1 2026.

• In Q1 2026, EPS (Basic) fell 108.78% year-over-year to -$14345.1; the TTM figure through Mar 2026 stood at $1.0 billion (down 87.65% YoY), while the FY2026 annual figure was $113115.4, up 25205412.31% from the prior year.
• EPS (Basic) was -$14345.1 for Q1 2026 at Takeda Pharmaceutical, down from $1.0 billion in the prior quarter.
• In the past five years, EPS (Basic) ranged from a high of $9.8 billion in Q3 2023 to a low of -$14345.1 in Q1 2026.
• Historically, EPS (Basic) has averaged $1.5 billion across 5 years, with a median of $646.3 million in 2022.
• The sharpest annual moves came in 2025 and 2026: EPS (Basic) soared 9073739260.24% in 2025, then slumped 108.78% in 2026.
• A 5-year view of EPS (Basic) shows it stood at $646.3 million in 2022, then jumped by 161.77% to $1.7 billion in 2023, then tumbled by 49.96% to $846.6 million in 2024, then rose by 20.95% to $1.0 billion in 2025, then sank by 100.0% to -$14345.1 in 2026.
• The last three EPS (Basic) figures came in at -$14345.1 (Q1 2026), $1.0 billion (Q4 2025), and $412389.0 (Q3 2025), per Business Quant data.